Arca
Skip to content
Tools
Tools

Hyaluronic acid

Oligosaccharide in Homo sapiens that 5 drugs act on.

  • Drugs that act on it: 5
  • Approved: 2
  • In phases 1 to 3: 3
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide 5

Approved2

  • Hyaluronidase
  • Hyaluronidase (human recombinant)

Phase 32

  • Condoliase
  • Hyaluronidase (ovine)

Phase 21

  • Pegvorhyaluronidase alfa

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Hyaluronic acid hydrolytic enzyme.
    HyaluronidaseApprovedBausch & LombProtein or peptideHydrolytic enzyme101
    Hyaluronidase (human recombinant)ApprovedBausch & LombProtein or peptideHydrolytic enzyme28
    CondoliasePhase 3—Protein or peptideHydrolytic enzyme0
    Hyaluronidase (ovine)Phase 3Bausch & LombProtein or peptideHydrolytic enzyme0
    Pegvorhyaluronidase alfaPhase 2Halozyme TherapeuticsProtein or peptideHydrolytic enzyme0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 14 in all, from ClinicalTrials.gov.
    Enzymatic Treatment for Postoperative Nasal Fibrosis After RhinoplastyHyaluronidaseNot applicableRecruitingResearch IncNov 17, 2026
    Effectiveness of Oxitard Gel Versus Physiotherapeutic and Pharmacological Interventions in Alleviating Oral Submucous Fibrosis: A Phase-II Randomized Control TrialHyaluronidasePhase 2Not yet recruitingDow University of Health SciencesNov 6, 2026
    Hyaluronidase Injections for Sclerodactyly in Patients With SclerodermaHyaluronidasePhase 2RecruitingStanford UniversityNov 4, 2026
    Prospective Evaluation of Recombinant Pbserum Plus® and Pbserum HA 2.0® in Aesthetic and Regenerative BioremodelingHyaluronidaseNot applicableNot yet recruitingAntony Barbosa InstituteNov 2, 2026
    Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple MyelomaHyaluronidase, Hyaluronidase (human recombinant)Phase 2 / Phase 3Not yet recruitingAlliance for Clinical Trials in OncologyOct 22, 2026
    VYVGART (Hytrulo) in Patients With Stiff Person Syndrome (SPS)HyaluronidasePhase 2 / Phase 3RecruitingThomas Jefferson UniversityOct 6, 2026
    A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of CareHyaluronidase, Hyaluronidase (human recombinant)Phase 1Not yet recruitingGlaxoSmithKlineAug 3, 2026
    Perioperative Haemostasis, Procedure-Related Pain After Physiological or Pharmacological Modifications of Local Anaesthesia Around the EyesHyaluronidasePhase 3Not yet recruitingPrince of Wales Hospital, Shatin, Hong KongJul 29, 2026
    Effect of Tergase Injection on Reducing Edema After Bilateral Total Knee ArthroplastyHyaluronidase (human recombinant)Not applicableNot yet recruitingMan Soo KimJul 15, 2026
    A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple SclerosisHyaluronidase (human recombinant)Phase 1Active, not recruitingHoffmann-La RocheJun 25, 2026
    Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM TrialHyaluronidase (human recombinant)Phase 2RecruitingNational Cancer Institute (NCI)May 26, 2026
    A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)Hyaluronidase (human recombinant)Phase 2Not yet recruitingHoffmann-La RocheMar 31, 2026
    A Study to Evaluate the Safety, PK, and Immunogenicity of Recombinant Human Hyaluronidase in Healthy SubjectsHyaluronidase (human recombinant)Phase 1Not yet recruitingShanghai Henlius BiotechMar 20, 2026
    Identifying Effective and Cost-Conscious Maintenance Daratumumab DosingHyaluronidase (human recombinant)Phase 2RecruitingEden BiltiboMar 20, 2026

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4495554, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.